Brief: Pulmatrix Inc Plans To Initiate Pur1800 Phase 2B Proof-Of-Concept Efficacy Study For Treatment Of Aecop In 2022

Pulmatrix

12/04/2021 22:47

April 12 (Reuters) - Pulmatrix Inc  PULM.O :
    * PULMATRIX INC - PLANS TO INITIATE PUR1800 PHASE 2B
PROOF-OF-CONCEPT EFFICACY STUDY FOR TREATMENT OF AECOP IN 2022
    * PULMATRIX TO REGAIN FULL RIGHTS TO PUR1800 AND NARROW
SPECTRUM
KINASE INHIBITOR PORTFOLIO
    * PULMATRIX INC - TERMINATION OF LICENSE, DEVELOPMENT AND
COMMERCIALIZATION AGREEMENT WITH LUNG CANCER INITIATIVE AT
JOHNSON & JOHNSON WILL RETURN PORTFOLIO TO PULMATRIX
    * PULMATRIX INC - TO CONTINUE DEVELOPMENT OF PUR1800 FOR
TREATMENT
OF ACUTE EXACERBATIONS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    * PULMATRIX INC - LONG-TERM TOXICOLOGY DATA IN Q3 2021 HAS
POTENTIAL TO BROADEN DEVELOPMENT TO ADDITIONAL INDICATIONS
REQUIRING CHRONIC DOSING

Source text for Eikon:  urn:newsml:reuters.com:*:nPnbpdRga
Further company coverage:  PULM.O 

 ((Reuters.Briefs@thomsonreuters.com;))